Injexate (Methotrexate)

Methotrexate acts as a folate antagonist by competitively inhibiting the enzyme dihydrofolate reductase. This blocks the conversion of dihydrofolate to tetrahydrofolate, a key cofactor for the synthesis of purine nucleotides and thymidylate, thereby reducing DNA, RNA, and protein production in rapidly dividing cells such as immune cells and cancer cells.

The dosing regimen for Injexate is individualized. A qualified prescriber determines the appropriate dose based on the specific condition, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here; the prescribing clinician will set the regimen.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended for use while breastfeeding because it can be excreted in breast milk and may affect the infant.

To request Injexate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Injexate (methotrexate) is a conventional disease‑modifying antirheumatic drug (DMARD) that offers oral or injectable options and is generally less expensive than biologic agents. Compared with newer biologics, methotrexate has a well‑established efficacy profile but may require more laboratory monitoring for liver and bone‑marrow toxicity.

Injexate should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Follow any additional handling instructions provided by the supplier to maintain product stability.

Injexate is given by subcutaneous injection. Healthcare professionals should use aseptic technique, select an appropriate injection site (such as the abdomen or thigh), rotate sites with each dose, and follow the prescribed volume and frequency as directed by the treating physician.

The most serious adverse effects of Injexate include severe liver toxicity (fibrosis or cirrhosis), profound bone‑marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and increased susceptibility to serious infections. Patients should be monitored regularly for these complications.

Injexate is contraindicated in pregnant women, individuals with severe hepatic disease, those with markedly impaired renal function, patients with active infections, and anyone who has demonstrated hypersensitivity to methotrexate or any component of the formulation.